Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer - PubMed (original) (raw)

Clinical Trial

doi: 10.1007/s10637-012-9869-8. Epub 2012 Aug 21.

Jean-Pascal Machiels, Dirk Schrijvers, Boris Alekseev, Mikhail Shkolnik, Simon J Crabb, Susan Li, Shobha Seetharam, Thomas A Puchalski, Chris Takimoto, Yusri Elsayed, Fitzroy Dawkins, Johann S de Bono

Affiliations

Clinical Trial

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Kenneth J Pienta et al. Invest New Drugs. 2013 Jun.

Abstract

Background: CC-chemokine ligand 2 (CCL2) promotes tumor growth by angiogenesis, macrophage infiltration and tumor invasion, and distant metastasis. Carlumab (CNTO 888) is a human IgG1κ mAb with high affinity and specificity for human CCL2. Preclinical data suggest carlumab may offer clinical benefit to cancer patients.

Methods: In a phase 2, open-label study, patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel received a 90-min infusion of 15 mg/kg carlumab q2w. The primary endpoint was response rate: change from baseline in skeletal lesions, extraskeletal lesions, and PSA values. Secondary endpoints included overall response rate (CR + PR) by RECIST, OS, PSA response, safety, pharmacodynamics, pharmacokinetics, immunogenicity.

Results: Forty-six patients were treated with 6 median (range 1, 26) doses. One patient had SD >6 months. There were no PSA or RECIST responses. Fourteen (34 %) patients had SD ≥ 3 months. Median OS was 10.2 (95 % CI: 5.2, not estimable) months. Twelve (39 %) patients reported improved pain scores. AEs occurred in 43 (93 %) patients, including 27 (59 %) with grade ≥ 3 AEs. Common grade ≥ 3 AEs were back (11 %) and bone (9 %) pain. Twenty (43 %) patients experienced SAEs, including pneumonia, spinal cord compression, back pain. No patient developed antibodies to carlumab. Steady-state serum concentrations were achieved after 3 repeated doses and were above the 10-μg/mL target concentration. Suppression of free CCL2 serum concentrations was briefly observed following each dose but was not sustained.

Conclusion: Carlumab was well-tolerated but did not block the CCL2/CCR2 axis or show antitumor activity as a single agent in metastatic CRPC.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Pharmacol. 2013 Oct;53(10):1020-7 - PubMed
    1. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 - PubMed
    1. Neoplasia. 2006 Jul;8(7):578-86 - PubMed
    1. Prostate. 2006 Sep 1;66(12):1311-8 - PubMed
    1. Clin Cancer Res. 2007 Dec 1;13(23):7053-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources